Authors
Jitu Pawar, Tanvi H Desai, Vipul G Gajera, Devesh U Kapoor, Priyanka R Chaudhari, Dhara S Parekh
Published in
Cytotechnology. Volume 78. Issue 5. Pages 173. Epub Aug 08, 2026.
Abstract
Abelmoschus moschatus i.a. a prostrate herb that is grown for its seed in tropical portions of Africa, South America, and Asia. It is a member of the Malvaceae family and also referred to Mushkdana. This plant has been reported for diuretic, antioxidant, antiproliferative, and antimicrobial activities along with its traditionally used in relieve spasms of the digestive track, aching joints and also considered as insecticide. Thus, anti-arthritic action of hydro-alcoholic extract of Abelmoschus moschatus seeds (EEAMS) were investigated in rats with arthritis caused by Complete Freund's adjuvant (CFA). In the present work powdered Abelmoschus moschatus seeds were extracted using 70% ethanol by the Soxhlet apparatus to prepare (EEAMS) and tested for phytochemical constituents. EEAMS was next tested for CFA induced arthritis in rats at dosages of 100, 200, and 400 mg/kg of weight by calculating paw volume, body weight, haematological and serum parameters, arthritic index, along with locomotor activity, antioxidant parameters and histopathological observation of ankle joints. EEAMS showed dose-related anti-arthritic effects by increasing body weight and reducing paw volume (100 mg/kg: 231 ± 5.59; 200 mg/kg: 236 ± 3.38; and 400 mg/kg: 237 ± 4.15) in association with control group (P < 0.05). It shown its considerable (P < 0.05) anti-arthritic action by elevate hemoglobin level and red blood cell, while concurrently declining C-reactive protein, erythrocyte sedimentation rate (ESR), WBC, and rheumatoid factor (100 mg/kg: 44.67 ± 3.37, 200 mg/kg: 40.05 ± 3.85, and 400 mg/kg: 36.39 ± 4.25) in different treatment group. The different dosages of EEAMS also improved dose dependent oxidative stress markers. Histopathological examinations also resulted in reduced joint damage in the feet. According to the results, EEAMS may be a viable therapeutic option of rheumatoid arthritis.
PMID:
42572519
Bibliographic data and abstract were imported from PubMed on 10 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 1
- Comments 0